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Abstract
Lunasin is a naturally occurring peptide isolated from soybeans and has been explored in
cancer treatment. Lunasin inhibits NF-κB activation and thus pro-inflammatory cytokine and
mediator production in macrophages. In this study we demonstrate that lunasin can effec-
tively suppress allergic airway inflammation in two murine models of asthma. In an OVA
+Alum sensitization model, intranasal lunasin treatment at the time of OVA challenges sig-
nificantly reduced total cells counts in bronchoalveolar lavage (BAL) fluid and eosinophilia,
peribronchiolar inflammatory infiltration, goblet cell metaplasia and airway IL-4 production.
In an OVA+LPS intranasal sensitization model, lunasin treatment either at the time of sensi-
tization or challenge has similar effects in suppress allergic airway inflammation including
significantly reduced total cell and eosinophil counts in BAL fluid, inflammatory gene Fizz1
expression in the lung, and IL-4 production by OVA re-stimulated cells from mediastinal
lymph nodes. We further show that intranasal instillation of OVA+lunasin significantly in-
creases OVA-specific regulatory T cell (Treg) accumulation in the lung comparing to OVA
only treatment. Taken together, our results suggest lunasin as an anti-inflammatory agent
can be potentially used in asthma therapy or as an adjuvant to enhance the induction of anti-
gen-specific Tregs and thus boost the efficacy of allergy immunotherapy.
Introduction
Prevalence of asthma has increased over the past 2–3 decades affecting 5–10% of the popula-
tion in many developed countries and is associated with a large socioeconomic burden [1]. Ma-
jority of asthma is associated with dysregulated T helper type-2 (Th2) immunity leading to
chronic eosinophilic inflammation in the airways. Recent studies demonstrated that asthma is
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rather heterogeneous and complex in pathogenesis involving wide range of innate and adaptive
immune cells and cytokines [2]. Treatments for asthma have been improved substantially in re-
cent years. However, current treatments such as antihistamines, leukotriene receptor antago-
nists and glucocorticoids are effective in temporarily relieve symptoms by suppressing
inflammation but do not change the chronic course of disease [3]. Furthermore, these therapies
failed to control the symptoms in 5–10% severe persistent asthma patients. New and more ef-
fective therapies are urgently required.
Induction of antigen-specific regulatory T (iTreg) cells is an important mechanism to main-
tain mucosal tolerance against harmless antigens and dampen the on-going allergic inflamma-
tion at exacerbation in animal models [4–7]. Induction of allergen-specific iTregs in allergic
patients is an essential step in allergen-specific immunotherapy and associates with clinical effi-
cacy and the suppression of allergic inflammation [8–10]. With the advantages of long-term
allergen-specific immune tolerance and disease-modifying effects, allergen-specific immuno-
therapy is the only available curative treatment for allergic diseases.
Lunasin was originally isolated from soybeans, and is a naturally occurring peptide contain-
ing 43 amino acids [11]. This peptide exhibits properties that have multiple health benefits,
and is a promising chemopreventive agent [12, 13] and therapeutic agent for cancer [14–17].
Studies demonstrate that lunasin inhibits NF-kB pathway and thus the production of proin-
flammatory cytokines and mediators by macrophages [18–20]. To further define the functions
of lunasin, we determine its effects on modulating allergic inflammation in the preclinical
study of asthma models. Allergic asthma was induced in BALB/c mice following systemic sen-
sitization with Alum-adjuvanted ovalbumin (OVA). Intransal administration of lunasin while
challenging with OVA alleviated allergic airway inflammation as evidenced by reduced eosino-
philic inflammatory cell infiltration in the bronchoalveolar lavage (BAL) and airway goblet cell
metaplasia. In an additional asthma model induced by intranasal LPS, administration of luna-
sin at either sensitization or challenge reduced airway inflammation. Attenuation of allergic in-
flammation following lunasin treatment was associated with increased numbers of OVA-
specific iTregs (CD4+ KJ1.26+ Foxp3+) in the lung. Collectively, these studies suggest a poten-
tial treatment with administration of lunasin to reduce allergic inflammation with added bene-
fit of promoting the accumulation of allergen-specific iTregs in airways which could have long-
lasting effects to dampen allergic responses.
Materials and Methods
Mice and Ethics Statement
BALB/c mice were purchased from Jackson Laboratory and maintained in pathogen-free con-
ditions. All studies were approved (protocol 10352) by the Indiana University School of Medi-
cine Animal Care and Use Committee.
Antibodies, lunasin peptide, and other reagents
Fluorochrome-conjugated monoclonal antibodies to mouse CD4, KJ1.26, IL-4, and Foxp3
were obtained from Biolegned. IL-4 ELISA kit was purchased from Biolegend. The lunasin pep-
tide with 43-amino acid was chemically synthesized with 97% purity by LifeTein (South Plain-
field, NJ) [16]. Ovalbumin (OVA, chromatographically purified) was fromWorthington
Biochemical Corp (Lakewood, NJ).
OVA+Alum sensitized allergic airway inflammation
BALB/c mice (female, 6–8 weeks old) were sensitized twice with intraperitoneal (i.p.) injection of
OVA (100 mg) adsorbed in Alum at days 0 and 7. One week following the second sensitization,
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mice were challenged with intranasal (i.n.) instillation of 100 mg of OVA alone or with lunasin
(20 mg/mouse) in a volume of 40 ml daily for 3 consecutive days (at days 14–16). Control mice
were treated with PBS only. One day after the last challenge (day 17), animals were euthanized
for analysis.
OVA+LPS sensitized allergic airway inflammation
OVA+LPS sensitization were performed as previously described [21]. BALB/c mice (female,
6–8 weeks old) were sensitized three times with i.n. instillation of OVA (100 mg) mixed with
LPS (50 ng) in a volume of 40 ml at days 0, 1, and 2. Mice were challenged with i.n. instillation
of OVA (100 mg) in a volume of 40 ml at days 14, 15, 18, and 19. One day after the last challenge
(at day 20), animals were euthanized for analysis.
The group of mice received lunasin at the time sensitization, 20 mg lunasin in 200 ml PBS
were injected intraperitoneally (i.p.) on days 0–2. For the group received lunasin at challenge,
20 mg lunasin were mixed with 100 mg OVA in 40 ml PBS and administered intranasally on
days 14, 15, 18 and 19.
Analysis of allergic airway inflammation
The bronchoalveolar lavage (BAL) fluid was obtained to determine the total cell counts. The
number for eosinophils was analyzed on cytospin slide after stained with a modified Wright-
Giemsa stain on a Hematek 2000 slide stainer (Bayer) [21, 22]. Intracellular cytokine staining
was performed in CD4+ T cells from mediastinal lymph nodes (MedLN) as previously de-
scribed [21, 22]. IL-4 concentration in BAL fluid and media fromMedLN cells cultured with
100 mg/ml OVA for three days was determined by ELISA.
Left side two lobes of the lungs were homogenized in Trizol reagent to extract RNA and
gene expression was determined by Taqman Realtime PCR (Life Technologies). Right side
three lobes of the lungs were fixed in neutral buffered formalin. Paraffin embedded sections
were stained with hematoxylin and eosin (H&E) or Periodic-acid Schiff (PAS) to evaluate the
infiltration of inflammatory cells and goblet cell metaplasia of the airways.
Adoptive cell transfer and OVA-specific iTreg induction
Naïve OVA-specific CD4+ T cells (KJ1.26+) were purified from DO11.10 transgenic mice ex-
pressing TCRs specific for an MHC class II restricted epitope of OVA323–339 (The Jackson Lab-
oratory). Two millions of naïve KJ1.26+ CD4+ T cells were adoptively transferred into BALB/c
mice. The following day these mice received daily i.n. instillation of 100 mg OVA in the pres-
ence or absence of 20 mg lunasin for 3 consecutive days. One day after the last instillation, ani-
mals were euthanized to collect the mediastinal lymph nodes and lungs for analysis of OVA-
specific iTregs by staining with Foxp3 expression.
Results
Lunasin attenuates allergic airway inflammation in mice sensitized with
OVA+Alum
Lunasin exhibited anti-inflammatory activity through inhibiting NF-kB pathway in macro-
phages [18, 19]. To study the effects of lunasin in suppressing allergic airway inflammation,
we sensitized BALB/c mice with OVA and Alum followed by intranasal (i.n.) OVA challenge
(Fig. 1A). 20 mg lunasin was mixed with 100 mg OVA to intranasally challenge the treatment
group of mice while control group was treated OVA or PBS only. The mice treated with OVA
+lunasin had significantly fewer total inflammatory cell counts in the BAL with reduced
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eosinophils compared with OVA treated mice (Fig. 1B). Gene found in inflammatory zone 1
(Fizz1) encodes a cysteine-rich secreted protein associated with pulmonary inflammation and
is capable of promoting expression of a-SMA and type I collagen at the early stages of airway
remodeling in murine model of asthma [23]. Although significantly higher than the PBS treat-
ed controls, mice received OVA+lunasin treatment had significantly reduced Fizz1 gene ex-
pression in their lungs than the OVA only challenged mice, (Fig. 1C).
Consistent to reduced pulmonary Fizz1 gene expression (Fig. 1C), histological study re-
vealed that lungs from control mice exhibited severe peribronchiolar eosinophilic infiltration
(Fig. 2A) whereas lunasin treated mice had greatly reduced inflammatory infiltration with scat-
tered eosinophils (Fig. 2B). One of the cardinal features of human asthma is airway goblet cell
metaplasia and mucus hyperproduction. While lungs from all the control mice had mild to
modest goblet cell metaplasia (Fig. 2C), only 2 out of 5 lunasin treated mice showed mild goblet
cell metaplasia in the airways (arrows in Fig. 2D).
Allergic airway inflammation is characterized with increased Th2 cytokines in the airways.
We measured IL-4 concentration in the BAL fluid by ELISA and found BAL IL-4 concentra-
tion was reduced from ~185 pg/ml in OVA treated mice to ~ 70 pg/ml in OVA+lunasin treated
mice (Fig. 3A). When lung draining mediastinal lymph node cells were restimulated and
stained for IL-4 expression, lunasin treated mice had significantly less IL-4+CD4+ cells com-
pared to control mice (Fig. 3B).
Lunasin alleviates allergic airway inflammation in OVA+LPS
sensitized mice
The OVA+Alummodel is a well-defined mouse asthma model resulting in Th2-mediated aller-
gic airway inflammation with many characteristics of asthma including airway eosinophilia,
mucus hyperproduction, and airway hyperresponsiveness [24, 25]. However, immunization
Figure 1. Lunasin alleviates allergic airway inflammation. (A) Experimental procedures. BALB/c mice
were sensitized intraperitoneally (i.p.) with 100 µg OVA absorbed on 1.3 mg Alum on days 0 and 7. Animals
were challenged intranasally with 100 µg OVA in the presence or absence of 20 µg lunasin on days 14 to 16
and sacrificed on day 17 for analysis. Control mice were treated similarly with PBS. (B) Total and eosinophil
cell counts in bronchoalveolar lavage (BAL) fluid. (C) Fizz1 gene expression in the lungs determined by
realtime PCR. Ctrl: PBS treated mice; O: OVA treated mice; O+L: OVA plus lunasin treated mice. Data
represent mean SEM (n = 5). *: p< 0.05; ** p< 0.01; ***: p< 0.001 by one-way analysis of variance with
Bonferroni’s post-hoc tests.
doi:10.1371/journal.pone.0115330.g001
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with OVA+Alum to induce sensitization is not a physiological route of allergen exposure.
Sensitization with antigen and LPS through the respiratory system, the anatomic site that
would normally encounter environmental allergens and LPS, provides a particular relevant
model to investigate immune responses in the pathogenesis of asthma [21, 26, 27]. Mice were
Figure 2. Lunasin reduces eosinophilic infiltration and goblet cell metaplasia.Mice were sensitized and challenged as described in Fig. 1A. (A and B)
Hematoxylin and eosin (H&E) stained lung sections from OVA (A) or OVA+lunasin treated (B) mice. Open arrow head: eosinophils. (C and D) Periodic acid–
Schiff (PAS) stained lung sections from OVA (C) or OVA+lunasin treated (D) mice. Arrow: mucus containing goblet cells.
doi:10.1371/journal.pone.0115330.g002
Figure 3. Lunasin reduces IL-4 expression in the airways.Mice were sensitized and challenged as
described in Fig. 1A. (A) IL-4 concentration in BAL fluid determined by ELISA. (B) Percentage of IL-4+ in CD4+ T
cells in the mediastinal lymph nodes (MedLN) determined by intracellular staining. Data represent mean SEM
(n = 5). **: p< 0.01; ***: p< 0.001 by one-way analysis of variance with Bonferroni’s post-hoc tests.
doi:10.1371/journal.pone.0115330.g003
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sensitized by intranasally delivery of 100 mg OVA in the presence of 50 ng LPS on days 0, 1 and
2 (Fig. 4A). To study the effects of lunasin on Th2 sensitization induced by OVA+LPS, one
group of mice also received intraperitoneal (i.p.) injection of 20 mg lunasin at the same time as
the mice were sensitized. Mice were then challenged intranasally with 100 mg OVA on days 14,
15, 18, and 19 in the presence or absence of 20 mg lunasin. Both groups of mice, treated with
20 mg lunasin either i.p. at sensitization or i.n. at challenge, had reduced total inflammatory cell
counts with significantly fewer eosinophils in BAL fluid than the control group (Fig. 4B). Like-
wise, pulmonary expression of Fizz1 gene in lunasin treated mice was also significantly lower
Figure 4. Lunasin alleviates allergic airway inflammation in an intranasal LPS sensitization model. (A)
Experimental procedures. BALB/c mice were sensitized intranasally with 100 µg OVA + 50 ng LPS on days 0
to 3. Mice were challenged with 100 µg OVA on days 14, 15, 18, and 19 and sacrificed on day 20 for analysis.
Lunasin (20 µg/mouse) were given either intraperitoneally (i.p.) at sensitization or intranasally (i.n.) at
challenge. (B) Total and eosinophil cell counts in BAL fluid. (C) Fizz1 gene expression in the lungs determined
by realtime PCR. (D) IL-4 concentration in media after cells frommediastinal lymph nodes were cultured with
100 µg OVA for 3 days. Ctrl: Control mice; LS: group of mice received lunasin at sensitization; LC: group of
mice received lunasin at challenge. Data represent mean SEM (n = 5). *: p< 0.05; *** p< 0.001 by one-
way analysis of variance with Bonferroni post-hoc test.
doi:10.1371/journal.pone.0115330.g004
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than that in control animals (Fig. 4C). When cultured in 100 mg OVA for three days, the medi-
astinal lymph node cells isolated from lunasin treated groups produced 0.5 ng/ml IL-4 compar-
ing to 2.5 ng/ml by the cells from control group (Fig. 4D).
Lunasin promotes antigen-specific iTreg development in airways
Induction of antigen-specific iTregs controls the severity of OVA-induced chronic airway in-
flammation [4] while blockade of iTreg development in neonatal mice maintains exaggerated
responses to inhaled house dust mite through to adulthood [28]. Since intranasal lunasin treat-
ment at the time of challenge dampens allergic airway inflammation in both OVA+Alum (i.p.)
and OVA+LPS (i.n.) sensitized mice, we hypothesize that lunasin can promote antigen-specific
iTreg development in the airways. To test this hypothesis, we purified OVA-specific naïve
CD4+ T cells from DO11.10 mice and injected 2 × 106 cells through tail vain into BALB/c recip-
ient mice. After inhalation of 100 mg OVA in the presence or absence of 20 mg lunasin for 3
days, mediastinal lymph nodes and lungs were harvested and made into single cell suspension.
Cells were stained with CD4, KJ1.26 and Foxp3 and analyzed by flow cytometry. Intranasal
lunasin treatment slightly increased antigen-specific (CD4+KJ1.26+) iTregs (Foxp3+) in the
mediastinal lymph nodes without reach significance (Fig. 5A). However, antigen-specific
iTregs in the lungs of lunasin treated mice were significantly higher and more than doubled
Figure 5. Lunasin promotes antigen-specific iTreg accumulation in the lung.OVA-specific naïve CD4+
T cells were purified from DO11.10 mice and 2 × 106 cells were adoptively transferred into BALB/c mice. The
recipient mice were treated with 100 µg OVA intranasally for three days in the presence or absence of 20 µg
lunasin. (A) OVA-specific iTregs in mediastinal lymph nodes (MedLN). (B) OVA-specific iTregs in lungs. (C)
OVA-specific iTregs in MedLN and lung 7 days after the last intranasal treatment. (D) OVA-specific iTregs in
MedLN and lung 14 days after the last intranasal treatment. Data represent mean SEM (n = 5). ns: not
significant; ***: p< 0.001 by Student’s t test.
doi:10.1371/journal.pone.0115330.g005
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than that of OVA only treated mice (Fig. 5B). The increased accumulation of antigen-specific
iTregs in the lungs of lunasin treated mice were maintained 7 days (Fig. 5C) and 14 days
(Fig. 5D) after the last intranasal treatment. The Foxp3+ DO11.10 T cells were mostly CD25+
and many were IL-10+ (S1 Fig.). The Foxp3+ DO11.10 T cells also expressed high levels of
CTLA-4, which is necessary for immune suppression and prevention of in vivo autoimmunity
[29, 30], suggesting these antigen-specific T cells are functional Tregs.
Discussion
The global prevalence of asthma and allergy has increased over the past 2–3 decades especially
within the developed in concert with growing clinical and socioeconomic burden [31]. Pro-
longed use of inhaled corticosteroids, especially at high doses, may cause systemic or local side
effects [32]. In this report, we demonstrate that inhaled soybean peptide lunasin is efficient in
alleviating allergic airway inflammation in both OVA+Alum and OVA+LPS sensitized mice
with significantly reduced Th2 cytokine expression, inflammatory infiltration, and goblet cell
metaplasia.
The NF-kB pathway is the master regulator of both innate and adaptive immune responses
in a wide variety of cell types. Activation of NF-kB pathway leads to transcription of genes im-
portant in cell survival, proliferation and inflammation, and has been demonstrated to play a
cardinal role in allergic airways disease [33]. Mice that lacked p50 or c-Rel subunits of NF-kB
were protected from the development of allergic airway disease [34, 35]. Several studies suggest
lunasin is capable of suppressing activation of NF-kB in both murine and human macrophages
and expression of pro-inflammatory cytokines and mediators, likely through its interaction
with the aVb3 integrin [18, 20]. The factor that lunasin also interacts with a5b1 integrin to
suppress NF-kB in colon cancer cells [15] suggest that, in addition to macrophages, lunasin
can exert its anti-inflammatory effect on airway epithelial cells and bronchial fibroblasts as the
a5b1 integrin—NF-kB pathway is operating in these cell types [36, 37].
In the asthmatic airways, various cells are activated to release cytokines, chemokines and
chemicals including reactive oxygen and nitrogen species to cause inflammation or amplify in-
flammation. Recent evidence indicates that endogenous reactive oxygen and nitrogen species
are responsible for the airway inflammation, and that the disequilibrium of the airway reducing
state is a determinant of asthma severity [38]. Studies show that lunasin is a potent scavenger
of peroxyl and superoxide radicals [39]. Lunasin significantly reduces intracellular reactive ox-
ygen species (ROS) concentration in macrophages stimulated by LPS [19] and human Caco-2
cells challenged by hydrogen peroxide and tert-butylhydroperoxide [39]. Therefore, in addition
to its anti-inflammatory activities through suppression NF-kB pathway, lunasin as a therapeu-
tic agent also possesses antioxidant activities to further dampen allergic airway inflammation
as seen in our studies.
While effective at controlling symptoms, current therapies for asthma and allergy do not
change the chronic course of disease [3]. In contrast to the drug treatment that offers tempo-
rary symptomatic relief, allergy immunotherapy is unique in altering the clinical course of al-
lergic diseases. One of the underlying mechanisms for allergy immunotherapy is the
generation of allergen-specific iTregs [40, 41]. Our results that lunasin stimulates antigen-
specific iTreg generation suggest that lunasin might be used as an adjuvant to enhance the effi-
cacy of allergy immunotherapy, with added benefits of its anti-inflammatory activity to lower
the risks associated with allergy immunotherapy.
It is also worth mentioning that systematic administration of lunasin (intraperitoneal injec-
tion) at the time of sensitization can prevent OVA+LPS induced airway sensitization so that
airway inflammation is significantly reduced upon OVA challenge. Since lunasin can be
Lunasin Alleviates Allergic Airway Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0115330 February 3, 2015 8 / 11
detected in the plasma after soybean protein ingestion [42], an association study of consump-
tion of soybean products and prevalence of sensitization against common allergens would be of
clinical relevance.
Supporting Information
S1 Fig. Characterization of OVA-specific regulatory T cells in the mediastinal lymph
nodes. Naive CD4+ T cells were purified from Foxp3eGFP DO11.10 mice using MACS (Milte-
nyi). 2 × 106 cells were adoptively transferred into wild type BALB/c mice and the recipients
were treated intranasally with 100 mg OVA in the presence or absence of 20 mg lunasin. 14 days
after the last treatment, mediastinal lymph nodes (MedLN) were collected for analysis. (A) Ex-
pression of CD25 and Foxp3 by the DO11.10 T cells. (B) Expression of IL-10 (intracellular
staining) by Foxp3+ DO11.10 T cells. (C) Expression of CTLA-4 (intracellular staining) by
Foxp3+ and Foxp3- DO11.10 T cells.
(PDF)
Author Contributions
Conceived and designed the experiments: HCC BZ. Performed the experiments: XY JZ CT GG
QW. Analyzed the data: XY JZ CT GG QWHCC BZ. Wrote the paper: HCC BZ.
References
1. Wenzel SE (2012) Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med
18: 716–725. doi: 10.1038/nm.2678 PMID: 22561835
2. Holgate ST (2012) Innate and adaptive immune responses in asthma. Nat Med 18: 673–683. doi: 10.
1038/nm.2731 PMID: 22561831
3. Akdis CA (2012) Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med
18: 736–749. doi: 10.1038/nm.2754 PMID: 22561837
4. Curotto de Lafaille MA, Kutchukhidze N, Shen S, Ding Y, Yee H, et al. (2008) Adaptive Foxp3+ regula-
tory T cell-dependent and-independent control of allergic inflammation. Immunity 29: 114–126. doi: 10.
1016/j.immuni.2008.05.010 PMID: 18617425
5. Curotto de Lafaille MA, Lafaille JJ (2009) Natural and adaptive foxp3+ regulatory T cells: more of the
same or a division of labor? Immunity 30: 626–635. doi: 10.1016/j.immuni.2009.05.002 PMID:
19464985
6. Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, et al. (2012) Extrathymically generated regula-
tory T cells control mucosal TH2 inflammation. Nature 482: 395–399. doi: 10.1038/nature10772 PMID:
22318520
7. Khare A, Krishnamoorthy N, Oriss TB, Fei M, Ray P, et al. (2013) Cutting edge: inhaled antigen upregu-
lates retinaldehyde dehydrogenase in lung CD103+ but not plasmacytoid dendritic cells to induce
Foxp3 de novo in CD4+ T cells and promote airway tolerance. J Immunol 191: 25–29. doi: 10.4049/
jimmunol.1300193 PMID: 23733880
8. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K (1998) Role of interleukin 10 in specific immuno-
therapy. J Clin Invest 102: 98–106. doi: 10.1172/JCI2250 PMID: 9649562
9. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, et al. (2003) IL-10 and TGF-beta coop-
erate in the regulatory T cell response to mucosal allergens in normal immunity and specific immuno-
therapy. Eur J Immunol 33: 1205–1214. doi: 10.1002/eji.200322919 PMID: 12731045
10. Radulovic S, JacobsonMR, Durham SR, Nouri-Aria KT (2008) Grass pollen immunotherapy induces
Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 121: 1467–1472,
1472 e1461. doi: 10.1016/j.jaci.2008.03.013 PMID: 18423565
11. Odani S, Koide T, Ono T (1987) Amino acid sequence of a soybean (Glycine max) seed polypeptide
having a poly(L-aspartic acid) structure. J Biol Chem 262: 10502–10505. PMID: 3611081
12. Galvez AF, Chen N, Macasieb J, de Lumen BO (2001) Chemopreventive property of a soybean peptide
(lunasin) that binds to deacetylated histones and inhibits acetylation. Cancer Res 61: 7473–7478.
PMID: 11606382
Lunasin Alleviates Allergic Airway Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0115330 February 3, 2015 9 / 11
13. Galvez AF, de Lumen BO (1999) A soybean cDNA encoding a chromatin-binding peptide inhibits mito-
sis of mammalian cells. Nat Biotechnol 17: 495–500. doi: 10.1038/8676 PMID: 10331812
14. Hsieh CC, Hernandez-Ledesma B, de Lumen BO (2010) Soybean peptide lunasin suppresses in vitro
and in vivo 7,12-dimethylbenz[a]anthracene-induced tumorigenesis. J Food Sci 75: H311–316. doi:
10.1111/j.1750-3841.2010.01861.x PMID: 21535606
15. Dia VP, Gonzalez de Mejia E (2011) Lunasin potentiates the effect of oxaliplatin preventing outgrowth
of colon cancer metastasis, binds to alpha5beta1 integrin and suppresses FAK/ERK/NF-kappaB sig-
naling. Cancer Lett 313: 167–180. doi: 10.1016/j.canlet.2011.09.002 PMID: 21963225
16. Chang HC, Lewis D, Tung CY, Han L, Henriquez SM, et al. (2014) Soypeptide lunasin in cytokine im-
munotherapy for lymphoma. Cancer Immunol Immunother 63: 283–295. doi: 10.1007/s00262-013-
1513-8 PMID: 24363024
17. Hernandez-Ledesma B, Hsieh CC, de Lumen BO (2009) Lunasin, a novel seed peptide for cancer pre-
vention. Peptides 30: 426–430. doi: 10.1016/j.peptides.2008.11.002 PMID: 19056440
18. de Mejia EG, Dia VP (2009) Lunasin and lunasin-like peptides inhibit inflammation through suppression
of NF-kappaB pathway in the macrophage. Peptides 30: 2388–2398. doi: 10.1016/j.peptides.2009.08.
005 PMID: 19682518
19. Hernandez-Ledesma B, Hsieh CC, de Lumen BO (2009) Antioxidant and anti-inflammatory properties
of cancer preventive peptide lunasin in RAW 264.7 macrophages. Biochem Biophys Res Commun
390: 803–808. doi: 10.1016/j.bbrc.2009.10.053 PMID: 19836349
20. Cam A, de Mejia EG (2012) RGD-peptide lunasin inhibits Akt-mediated NF-kappaB activation in human
macrophages through interaction with the alphaVbeta3 integrin. Mol Nutr Food Res 56: 1569–1581.
doi: 10.1002/mnfr.201200301 PMID: 22945510
21. Zhang Y, Zhou X, Zhou B (2012) DC-derived TSLP promotes Th2 polarization in LPS-primed allergic
airway inflammation. Eur J Immunol 42: 1735–1743. doi: 10.1002/eji.201142123 PMID: 22585305
22. Zhou B, Headley MB, Aye T, Tocker J, Comeau MR, et al. (2008) Reversal of Thymic Stromal Lympho-
poietin-Induced Airway Inflammation through Inhibition of Th2 Responses. J Immunol 181: 6557–
6562. doi: 10.4049/jimmunol.181.9.6557 PMID: 18941246
23. Dong L, Wang SJ, Camoretti-Mercado B, Li HJ, Chen M, et al. (2008) FIZZ1 plays a crucial role in early
stage airway remodeling of OVA-induced asthma. J Asthma 45: 648–653. doi: 10.1080/
02770900802126941 PMID: 18951255
24. Zhou B, Comeau MR, Smedt TD, Liggitt HD, Dahl ME, et al. (2005) Thymic stromal lymphopoietin as a
key initiator of allergic airway inflammation in mice. Nat Immunol 6: 1047–1053. doi: 10.1038/ni1247
PMID: 16142237
25. Lei L, Zhang Y, YaoW, Kaplan MH, Zhou B (2011) Thymic stromal lymphopoietin interferes with airway
tolerance by suppressing the generation of antigen-specific regulatory T cells. J Immunol 186: 2254–
2261. doi: 10.4049/jimmunol.1002503 PMID: 21242516
26. Piggott DA, Eisenbarth SC, Xu L, Constant SL, Huleatt JW, et al. (2005) MyD88-dependent induction of
allergic Th2 responses to intranasal antigen. J Clin Invest 115: 459–467. doi: 10.1172/JCI22462
PMID: 15650773
27. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, et al. (2002) Lipopolysaccharide-en-
hanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med
196: 1645–1651. doi: 10.1084/jem.20021340 PMID: 12486107
28. Gollwitzer ES, Saglani S, Trompette A, Yadava K, Sherburn R, et al. (2014) Lung microbiota promotes
tolerance to allergens in neonates via PD-L1. Nat Med 20: 642–647. doi: 10.1038/nm.3568 PMID:
24813249
29. Tai X, Van Laethem F, Pobezinsky L, Guinter T, Sharrow SO, et al. (2012) Basis of CTLA-4 function in
regulatory and conventional CD4(+) T cells. Blood 119: 5155–5163. doi: 10.1182/blood-2011-11-
388918 PMID: 22403258
30. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, et al. (2008) CTLA-4 control over Foxp3+
regulatory T cell function. Science 322: 271–275. doi: 10.1126/science.1160062 PMID: 18845758
31. Hankin CS, Cox L (2014) Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Aller-
gy Clin Immunol 14: 363–370. doi: 10.1097/ACI.0000000000000084 PMID: 24936851
32. Li XM (2011) Treatment of asthma and food allergy with herbal interventions from traditional chinese
medicine. Mt Sinai J Med 78: 697–716. doi: 10.1002/msj.20294 PMID: 21913200
33. Janssen-Heininger YM, Poynter ME, Aesif SW, Pantano C, Ather JL, et al. (2009) Nuclear factor kap-
paB, airway epithelium, and asthma: avenues for redox control. Proc Am Thorac Soc 6: 249–255. doi:
10.1513/pats.200806-054RM PMID: 19387025
Lunasin Alleviates Allergic Airway Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0115330 February 3, 2015 10 / 11
34. Yang L, Cohn L, Zhang DH, Homer R, Ray A, et al. (1998) Essential role of nuclear factor kappaB in the
induction of eosinophilia in allergic airway inflammation. J Exp Med 188: 1739–1750. doi: 10.1084/jem.
188.9.1739 PMID: 9802985
35. Donovan CE, Mark DA, He HZ, Liou HC, Kobzik L, et al. (1999) NF-kappa B/Rel transcription factors:
c-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation. J Immunol 163:
6827–6833. PMID: 10586083
36. Han SW, Roman J (2006) Fibronectin induces cell proliferation and inhibits apoptosis in human bron-
chial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B. Oncogene 25:
4341–4349. doi: 10.1038/sj.onc.1209460 PMID: 16518410
37. Loubaki L, Semlali A, Boisvert M, Jacques E, Plante S, et al. (2010) Crosstalk between T cells and bron-
chial fibroblasts obtained from asthmatic subjects involves CD40L/alpha 5 beta 1 interaction. Mol
Immunol 47: 2112–2118. doi: 10.1016/j.molimm.2010.03.011 PMID: 20471683
38. Comhair SA, Erzurum SC (2010) Redox control of asthma: molecular mechanisms and therapeutic op-
portunities. Antioxid Redox Signal 12: 93–124. doi: 10.1089/ars.2008.2425 PMID: 19634987
39. Garcia-Nebot MJ, Recio I, Hernandez-Ledesma B (2014) Antioxidant activity and protective effects of
peptide lunasin against oxidative stress in intestinal Caco-2 cells. Food Chem Toxicol 65: 155–161.
doi: 10.1016/j.fct.2013.12.021 PMID: 24365261
40. Nelson HS, Norman PS (2014) Allergen-specific immunotherapy. Chem Immunol Allergy 100: 333–338.
doi: 10.1159/000360047 PMID: 24925414
41. Fujita H, Soyka MB, Akdis M, Akdis CA (2012) Mechanisms of allergen-specific immunotherapy. Clin
Transl Allergy 2: 2. doi: 10.1186/2045-7022-2-2 PMID: 22409879
42. Dia VP, Torres S, De Lumen BO, Erdman JW Jr, De Mejia EG (2009) Presence of lunasin in plasma of
men after soy protein consumption. J Agric Food Chem 57: 1260–1266. doi: 10.1021/jf803303k PMID:
19199603
Lunasin Alleviates Allergic Airway Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0115330 February 3, 2015 11 / 11
